Citadel Advisors
NVNO

Citadel Advisors’s enVVeno Medical NVNO Stock Holding History

Citadel Advisors’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-317
Closed -$3.56K – 13831
2025
Q4 		$3.56K Sell
317
-26
-8% -$505 ﹤0.01% 12473
2025
Q3 		$10.9K Buy
+343
New +$35K ﹤0.01% 12560
2025
Q2 		– Sell
-71
Closed -$6.58K – 14275
2025
Q1 		$6.58K Buy
71
+68
+2,267% +$7.58K ﹤0.01% 13744
2024
Q4 		$302 Sell
3
-146
-98% -$16.3K ﹤0.01% 14348
2024
Q3 		$17.5K Sell
149
-25
-14% -$4.59K ﹤0.01% 12884
2024
Q2 		$32K Sell
174
-335
-66% -$58.5K ﹤0.01% 12190
2024
Q1 		$96.8K Buy
509
+315
+162% +$56.5K ﹤0.01% 11408
2023
Q4 		$35K Buy
+194
New +$30.9K ﹤0.01% 12133
2023
Q3 		– Sell
-40
Closed -$4.31K – 14833
2023
Q2 		$4.31K Buy
+40
New +$5.19K ﹤0.01% 13607
2022
Q4 		– Sell
-286
Closed -$63K – 15268
2022
Q3 		$63K Buy
+286
New +$60.9K ﹤0.01% 11462

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's NVNO Position: Q1 2026 in Review

Citadel Advisors sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 1,221 shares — an estimated $13.7K sold.

Citadel Advisors first reported a position in NVNO in Q4 2018 and held it in 15 quarters. The position peaked at $321K in Q4 2024. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • Citadel Advisors reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,221 enVVeno Medical shares in Q1 2026, an estimated $13.7K.
  • Citadel Advisors first reported a position in enVVeno Medical in Q4 2018 and held it in 15 quarters.
  • Citadel Advisors's enVVeno Medical position peaked at $321K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.